Fintiv and Discretionary Denial of IPR Institution

When a district-court (or ITC) case is already running, the USPTO can still refuse to institute an IPR even if the petition looks institution-worthy on the merits. Apple v. Fintiv supplies the six-factor framework; later Director memoranda (including March 26, 2025 workload processes, October 17, 2025 Director institution, and March 11, 2026 manufacturing/small-business factors) reshape how those factors are weighed. This page is for litigators timing a petition or stay motion and for readers who hear "Fintiv denial" on a docket.

Institution of inter partes review is not automatic. Under 35 U.S.C. 314(a), the Director may not institute unless the petition and any response show a reasonable likelihood that the petitioner would prevail on at least one challenged claim. Separately, the statute frames institution as a discretionary gate: the Office may decline to institute even when that threshold is met. Under current practice (Director memorandum of October 17, 2025, effective October 20, 2025), the Director determines whether to institute IPR and PGR and typically issues a summary notice granting or denying institution. "Discretionary denial" is the label for withholding institution to manage parallel litigation, workload, settled expectations, or other policy considerations before or alongside the merits screen.

Where Fintiv came from

In NHK Spring Co. v. Intri-Plex Technologies, Inc., IPR2018-00752 (PTAB Sept. 12, 2018) (precedential), the Board treated an advanced parallel district case, including an earlier trial date, as a reason to deny institution under section 314(a). In Apple Inc. v. Fintiv, Inc., IPR2020-00019, Paper 11 (PTAB Mar. 20, 2020) (precedential), the Board collected a nonexclusive six-factor test for that parallel-proceeding analysis. The Federal Circuit has described the NHK-Fintiv instructions as Board policy guidance that binds the Board, not as notice-and-comment legislative rules. See Apple Inc. v. Squires, No. 24-1864 (Fed. Cir. Feb. 13, 2026).

The six Apple v. Fintiv factors

As restated when the Board applied them in the same proceeding (Paper 15), the factors ask:

Whether the court granted a stay or evidence exists that one may be granted if a proceeding is instituted.
Proximity of the court's trial date to the Board's projected statutory deadline for a final written decision.
Investment in the parallel proceeding by the court and the parties.
Overlap between issues raised in the petition and in the parallel proceeding.
Whether the petitioner and the defendant in the parallel proceeding are the same party.
Other circumstances that impact the Board's exercise of discretion, including the merits.

The Board takes a holistic view: efficiency, fairness, and the integrity of the patent system, not a single bright-line score. A fast district trial date can weigh toward denial; a stay (or a credible path to one) can weigh the other way. Heavy claim-construction or validity work already done in court increases the cost of running a second track. Overlap and party identity ask whether the IPR would truly simplify the court case or just duplicate it. Merits matter, but they are part of the mix rather than a free pass.

Timing: district clocks and the IPR calendar

Practically, Fintiv is a race-and-coordination doctrine. Petitioners watch the district schedule (trial settings, Markman dates, discovery cutoffs) against the Board's statutory final-written-decision clock. Patent owners watch the same calendar when opposing institution or seeking a stay. A Sotera-style stipulation (petitioner agrees that, if IPR is instituted, it will not pursue in court or at the ITC grounds raised or that reasonably could have been raised in the IPR) can reduce overlap under factor 4; after the Office rescinded the June 2022 interim memo, such a stipulation is highly relevant but not automatically dispositive under the March 24, 2025 Board guidance.

Published guidance on discretionary institution

Policy here moves by public memoranda and precedential designations, not by unpublished private rules. Themes visible on the USPTO's own releases include:

February 28, 2025: the Office rescinded the June 21, 2022 Interim Procedure on discretionary denials, restoring primary reliance on Fintiv, Sotera, and related Board precedent.
March 24, 2025 (Chief Judge Boalick guidance): apply Fintiv when there is a parallel ITC investigation; treat a timely Sotera stipulation as highly relevant but not alone dispositive; consider trial-date evidence including median time-to-trial statistics; weigh merits in the holistic assessment, but do not treat compelling merits as automatically ending the analysis.
March 26, 2025 (Interim Processes for PTAB Workload Management): the memorandum separated discretionary considerations from merits, with the Director consulting at least three PTAB judges. It introduced separate briefing and listed considerations such as settled expectations. Later Office guidance controls current briefing deadlines, described below.
October 17, 2025 (Director Institution of AIA Trial Proceedings; effective October 20, 2025): the Director determines institution for all IPR and PGR proceedings and issues summary notices for routine grants and denials. The memo builds on the March 26 interim discretionary process and supersedes it to the extent that routine institution decisions are limited to summary notices and merit-based institution is not referred to a three-member panel in the ordinary course. Instituted trials still go to a three-member PTAB panel.
March 11, 2026 (Director Squires memorandum): when deciding institution, consider U.S. manufacturing of accused products and of patent-owner competing products, and whether the petitioner is a small business sued on the patent at issue.
February 13, 2026: the Federal Circuit in Apple v. Squires held that the NHK-Fintiv policy instructions are general statements of policy exempt from APA notice-and-comment rulemaking.

Read each memorandum with later guidance that may amend it. In particular, the October 17, 2025 memorandum changed who decides institution while preserving separate discretionary briefing.

Discretionary briefing under current Office process

The USPTO's current Interim Director Discretionary Process page, sections II.B and III.B, measures both ordinary briefing deadlines from the Notice of Filing Date Accorded (NFDA): the patent owner's discretionary-denial brief is due within two months, and the petitioner's opposition is due within three months. The opposition deadline is not one month after the patent owner files. Parties cannot extend these deadlines by stipulation; consult the Office's process for requesting an extension. Under the October 17, 2025 memorandum, effective October 20, the Director decides institution after consulting at least three PTAB judges. Instituted trials proceed before three-member panels.

How this sits next to stays, ITC, and willfulness

Discretionary denial concerns whether an Office trial begins. A district-court stay pending IPR is a separate case-management decision, as Murata Machinery USA, Inc. v. Daifuku Co., Ltd. explains. Under 28 U.S.C. 1659, a party that is also an ITC respondent may obtain a mandatory district-court stay of overlapping issues if it requests the stay within the statutory time limit. These are different decisions with different requirements.

Practice pointers

Build a one-page timing chart before you file or oppose: complaint service date, 315(b) IPR bar date, scheduled trial or ITC target date, and the Board's projected FWD date.
If you offer a Sotera stipulation, file it before institution and treat it as factor-4 evidence, not as a guaranteed institution ticket under current guidance.
On the patent-owner side, document real district/ITC investment and concrete overlap; on the petitioner side, document stay practice, schedule slip risk, and any merits strength the holistic test still considers.
Separate forums in client advice: Fintiv is about whether the Office opens a second validity track, not about whether the complaint stated a claim or whether damages will be enhanced.

Where should I read next?

For plaintiff-side effects, see How does Fintiv affect my district court case?. For whether to petition, see Should I challenge the patent at the PTAB? and What is an IPR?. For stay practice (and how it differs from 1659), see Can I stay the district court case if I file at the PTAB?. For the reexam alternative, see the reexamination FAQ. Dual-track ITC coverage lives on the dual-track breakout.

Authority in short

Primary public authorities for this page: 35 U.S.C. 314(a); NHK Spring Co. v. Intri-Plex Technologies, Inc., IPR2018-00752 (PTAB Sept. 12, 2018) (precedential); Apple Inc. v. Fintiv, Inc., IPR2020-00019, Paper 11 (PTAB Mar. 20, 2020) (precedential), applied in Paper 15; Sotera Wireless, Inc. v. Masimo Corp., IPR2020-01019, Paper 12 (PTAB Dec. 1, 2020) (precedential); USPTO rescission of the June 21, 2022 Interim Procedure (Feb. 28, 2025) and Chief Judge Boalick guidance (Mar. 24, 2025); USPTO Interim Processes for PTAB Workload Management (Mar. 26, 2025); USPTO Interim Director Discretionary Process page; USPTO Director Institution of AIA Trial Proceedings (Oct. 17, 2025); Director Squires memorandum on U.S. manufacturing and small-business considerations (Mar. 11, 2026); Apple Inc. v. Squires, No. 24-1864 (Fed. Cir. Feb. 13, 2026); 28 U.S.C. 1659 (ITC parallel stay contrast). This page is general commentary, not advice on any live matter.